Find Clinical Trial

An International Phase Ib Multicentre Study to Characterize the Safety and Tolerability of Intravenously Administered S64315 a Selective Mcl-1 Inhibitor, in Combination With Orally Administered Venetoclax a Selective Bcl-2 Inhibitor in Patients With Acute Myeloid Leukaemia


← Back
Study Phase Phase 1
Therapeutic Area Oncology
Active Substance S064315
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS064315
Protocol CodeCL1-64315-002
EudraCT Code2018-001809-88
NCT CodeNCT03672695


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.